Notice of Intent to Publish the Reissuance of PAR-18-422, NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)

0
168

Opportunity ID:332685
Opportunity Number:NOT-NS-21-055
Opportunity Title:Notice of Intent to Publish the Reissuance of PAR-18-422, NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)
Opportunity Category:Discretionary
Opportunity Category Explanation:
Funding Instrument Type:Cooperative Agreement
Category of Funding Activity:Health
Category Explanation:
CFDA Number(s):93.853
Eligible Applicants:State governments
County governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:
Agency Code:HHS-NIH11
Agency Name:Department of Health and Human Services
National Institutes of Health
Posted Date:Apr 06, 2021
Last Updated Date:Apr 06, 2021
Estimated Synopsis Post Date:May 04, 2021
Fiscal Year:2022
Award Ceiling:
Award Floor:
Estimated Total Program Funding:
Expected Number of Awards:
Description:This notice informs the research community that the National Institute of Neurological Disorders and Stroke (NINDS) intends to reissue Funding Opportunity Announcement (FOA) PAR-18-422 "NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)". The FOA is expected to be published in May 2021 with an expected application due date in June 2021. This FOA will no longer utilize the U01 activity code. Instead, it will be reissued using the UG3/UH3 grant mechanism. This Notice is being published now to inform prospective applicants in advance of this modification and to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. Details of the planned FOA are provided below.
Version:1





Visit the Official Webpage For More Details on Notice of Intent to Publish the Reissuance of PAR-18-422, NINDS Efficacy Clinical Trials (UG3/UH3 Clinical Trial Required)

LEAVE A REPLY

Please enter your comment!
Please enter your name here